CurrentCignaPolicy N/A

Drug Quantity Management Policy — Oral COVID-19 Antivirals (Lagevrio, Paxlovid)

Defines quantity limits and exception (one-time override) criteria for Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir/ritonavir) for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyDrug Quantity Management Policy — Oral COVID-19 Antivirals

Policy CodePolicy N/A

Change TypeMaterial revision — override interval reduced

Effective DateN/A

Next Review DateSep 11, 2024

Key ActionRequest one-time override only if repeat COVID-19 diagnosis is documented and at least 30 days have elapsed since completion of the prior course.

SourceLink

POLICY UPDATE CHANGES

Override criteria were updated to require at least 30 days to have elapsed since completion of the initial course of treatment for COVID-19 (previously 90 days).

Policy statement clarifies that 'one-time' approvals are provided for 30 days in duration.

40Max Lagevrio per 180 days

30Max Paxlovid (30-tab) per 180 days

20Max Paxlovid (20-tab) per 180 days

5Recommended course duration (days)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Minimum interval for override (days)

Coverage Criteria

One-time override for additional course

Exceptions to the quantity limits are covered as medically necessary when the following criteria are met; any other exception is considered not medically necessary.

Lagevrio one-time override

Repeat diagnosis: Patient has a repeat diagnosis of COVID-19 (new diagnosis unrelated to initial treated infection)
Interval since prior treatment: At least 30 days have elapsed since completion of the initial course of Lagevrio for treatment of COVID-19>=30 days

Paxlovid one-time override

Repeat diagnosis: Patient has a repeat diagnosis of COVID-19 (new diagnosis unrelated to initial treated infection)
Interval since prior treatment: At least 30 days have elapsed since completion of the initial course of Paxlovid for treatment of COVID-19>=30 days

Exceptions to the Drug Quantity Limits for Lagevrio and Paxlovid are covered as medically necessary only when the specific one-time override criteria described in this policy are met; any other exception is considered not medically necessary.

Requests that exceed the listed quantity limits for Lagevrio or Paxlovid that do not meet the stated one-time override criteria are considered not medically necessary and will be denied.

Initial Therapy Criteria

Initial therapy

Recommended dosing and initiation window

Dosing and initiation: Treatment should be initiated as soon as possible and within 5 days of symptom onset; each course is 5 days per product labeling<=5 days from symptom onset

Complete full 5-day course

Drug Quantity Limits

inv-12: Lagevrio (molnupiravir) 200 mg capsules — quantity limit value

Quantity limit40 capsules per 180 days (bottle of 40)

Unit200 mg capsules

Relevant productLagevrio (molnupiravir)

Source noteSee Drug Quantity Limits: Maximum Quantity per 180 Days = 40 capsules

inv-13: Paxlovid co-packaged tablets (30-tablet carton) — quantity limit value

Quantity limit30 tablets per 180 days (one 30-tablet carton)

Unittablets (30-tablet carton contains five daily-dose blister cards)

Provider Actions & Prior Authorization

Prior Authorization

Quantity limits and one-time override prior authorization

Quantity limits apply at point of sale for oral COVID-19 antivirals. If the Drug Quantity Management rule is not met at point of service, coverage will be reviewed against the criteria below. One-time approvals are clinician-reviewed and provided for 30 days.

Lagevrio (molnupiravir) — Maximum: 40 capsules per 180 days
Paxlovid (nirmatrelvir + ritonavir) — Maximum: 30 tablets per 180 days (30-tablet carton) or 20 tablets per 180 days (20-tablet carton)

Note

Provider action: request operational details

For patients with a repeat, new episode of COVID-19, providers may request a one-time override for an additional full course only when documentation shows the new diagnosis is unrelated to the initial treated episode and timing requirements are met. All override requests will be reviewed by a clinician (nurse or pharmacist).

Lagevrio — one-time additional course = 40 capsules
Paxlovid — one-time additional course = one 30-tablet carton or one 20-tablet carton

Definitions

inv-09: Lagevrio definition entry

TermLagevrio

DefinitionA nucleoside analogue (molnupiravir) that inhibits SARS-CoV-2 replication by viral mutagenesis; authorized for treatment of mild-to-moderate COVID-19 in adults at high risk for progression when alternative FDA-approved or authorized options are not accessible or clinically appropriate.

LimitationsNot authorized for patients <18 years, not authorized for initiation during hospitalization, not for pre- or post-exposure prophylaxis, and not for use longer than 5 consecutive days.

inv-10: Paxlovid definition entry

TermPaxlovid

DefinitionCo-packaged nirmatrelvir tablets with ritonavir tablets; nirmatrelvir is a SARS-CoV-2 main protease inhibitor and ritonavir is a CYP3A inhibitor; FDA-approved for treatment of mild-to-moderate COVID-19 in adults at high risk for progression.

Background

Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir co-packaged with ritonavir) are oral antivirals authorized for treatment of mild-to-moderate COVID-19 in patients at high risk for progression. Each product is intended as a 5-day course; supply presentations relevant to this policy are a bottle of 40 Lagevrio 200 mg capsules and Paxlovid co-packaged cartons of 20 or 30 tablets. Quantity limits are applied per 180 days to align with these course sizes, and a one-time override process exists to permit an additional full course when the documented repeat diagnosis and interval criteria are satisfied.

Policy Summary

PayerCigna

PolicyDrug Quantity Management Policy — Oral COVID-19 Antivirals

Policy CodePolicy N/A

Change TypeMaterial revision — override interval reduced

Effective DateN/A

Next Review DateSep 11, 2024

Key ActionRequest one-time override only if repeat COVID-19 diagnosis is documented and at least 30 days have elapsed since completion of the prior course.

SourceLink

On This Page

Relevant productPaxlovid (nirmatrelvir; ritonavir co-packaged)

Source noteSee Drug Quantity Limits: Maximum Quantity per 180 Days = 30 tablets (1 carton of 5 blister cards)

inv-14: Paxlovid co-packaged tablets (20-tablet carton) — quantity limit value

Quantity limit20 tablets per 180 days (one 20-tablet carton)

Unittablets (20-tablet carton contains five daily-dose blister cards)

Relevant productPaxlovid (nirmatrelvir; ritonavir co-packaged)

Source noteSee Drug Quantity Limits: Maximum Quantity per 180 Days = 20 tablets (1 carton of 5 blister cards)

Documentation Required

Required documentation and review

Required documentation must demonstrate that the request meets the benefit plan terms and the policy criteria. Submit clinical notes showing: the new COVID-19 diagnosis, date(s) of prior treatment completion, and evidence that at least 30 days have elapsed since completion of the initial antiviral course. Include prescription details (drug, strength, quantity) and any relevant lab or diagnostic results. Coverage determinations are ultimately governed by the member's benefit plan.

Document new, unrelated COVID-19 diagnosis and start date
Document completion date of prior antiviral course and that >= 30 days have passed
Include prescription/carton details (Lagevrio 40-cap bottle; Paxlovid 20- or 30-tablet carton)

Denial Risk

Denial triggers for quantity limits

Requests that do not meet the stated criteria will be denied at point of service or on review. Denials will occur when: the request exceeds the 180-day quantity limit and no valid one-time override criteria are met, the repeat diagnosis is not clearly distinct from the initial treated episode, or documentation fails to show completion date and the required 30-day interval.

Denial triggers: quantity exceeds 40 capsules (Lagevrio) or exceeds 20/30 tablets (Paxlovid) per 180 days without approved override
Denial triggers: insufficient documentation that the repeat diagnosis is new/unrelated
Denial triggers: less than 30 days since completion of prior course

PackagingSupplied in two dose-packs: a 30-tablet carton (five daily-dose blister cards: four nirmatrelvir + two ritonavir per day) and a 20-tablet carton (five daily-dose blister cards: two nirmatrelvir + two ritonavir per day).